[go: up one dir, main page]

CO5090905A1 - Formulaciones de fsh o una variante de fsh procdutos y meto- dos - Google Patents

Formulaciones de fsh o una variante de fsh procdutos y meto- dos

Info

Publication number
CO5090905A1
CO5090905A1 CO99045916A CO99045916A CO5090905A1 CO 5090905 A1 CO5090905 A1 CO 5090905A1 CO 99045916 A CO99045916 A CO 99045916A CO 99045916 A CO99045916 A CO 99045916A CO 5090905 A1 CO5090905 A1 CO 5090905A1
Authority
CO
Colombia
Prior art keywords
fsh
formulations
variation
methods
products
Prior art date
Application number
CO99045916A
Other languages
English (en)
Inventor
James Arthur Hoffmann
Lu Jirong
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27536687&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO5090905(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CO5090905A1 publication Critical patent/CO5090905A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Otolaryngology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Dispersion Chemistry (AREA)
  • Pregnancy & Childbirth (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Una formulación estable que comprende por lo menos una FSH ó una variante de FSH que contienen una subunidad alfa y una subunidad beta, y buffer de fosfatos que comprende solución salina ó una sal, en donde dicha FSH ó dicha variante de FSH comprenden por lo menos 90% de dímeros de FSH ó de una variante de FSH después de 60 días a 23°C.
CO99045916A 1998-07-23 1999-07-21 Formulaciones de fsh o una variante de fsh procdutos y meto- dos CO5090905A1 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US9390698P 1998-07-23 1998-07-23
US9461198P 1998-07-30 1998-07-30
US9476798P 1998-07-31 1998-07-31
US9871198P 1998-09-01 1998-09-01
US10069698P 1998-09-17 1998-09-17

Publications (1)

Publication Number Publication Date
CO5090905A1 true CO5090905A1 (es) 2001-10-30

Family

ID=27536687

Family Applications (1)

Application Number Title Priority Date Filing Date
CO99045916A CO5090905A1 (es) 1998-07-23 1999-07-21 Formulaciones de fsh o una variante de fsh procdutos y meto- dos

Country Status (23)

Country Link
EP (2) EP1188444B1 (es)
JP (1) JP4719357B2 (es)
KR (1) KR20010083126A (es)
CN (1) CN1309567A (es)
AR (1) AR020618A1 (es)
AT (2) ATE228850T1 (es)
AU (1) AU776823B2 (es)
BR (1) BR9912243A (es)
CA (1) CA2335340C (es)
CO (1) CO5090905A1 (es)
DE (2) DE69904262T3 (es)
DK (1) DK0974359T4 (es)
ES (2) ES2250290T3 (es)
ID (1) ID28747A (es)
IL (1) IL140984A0 (es)
MY (1) MY135913A (es)
NO (1) NO20010326L (es)
NZ (1) NZ508874A (es)
PE (1) PE20000939A1 (es)
PL (1) PL346127A1 (es)
PT (1) PT974359E (es)
SI (1) SI0974359T1 (es)
WO (1) WO2000004913A1 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6414123B1 (en) 1997-10-21 2002-07-02 Vitro Diagnostics, Inc. Method for purifying FSH
US20030166525A1 (en) 1998-07-23 2003-09-04 Hoffmann James Arthur FSH Formulation
EP1169053A1 (en) 1999-04-13 2002-01-09 Inhale Therapeutic Systems, Inc. Pulmonary administration of dry powder formulations for treating infertility
TW201002201A (en) 2001-03-01 2010-01-16 Lonza Ag Preservative blends containing quaternary ammonium compounds
UA91960C2 (ru) * 2003-04-02 2010-09-27 Эйрес Трейдинг С.А. Жидкие фармацевтические композиции fsh и lh
US7741268B2 (en) * 2003-04-02 2010-06-22 Ares Trading S.A. Liquid pharmaceutical formulations of FSH and LH together with a non-ionic surfactant
HRP20130242T1 (hr) 2003-06-20 2013-04-30 Ares Trading S.A. Smrzavanjem osušene formulacije fsh/lh
KR101105871B1 (ko) * 2005-09-27 2012-01-16 주식회사 엘지생명과학 인 난포자극호르몬의 안정한 용액 제형
US8518881B2 (en) 2007-02-08 2013-08-27 Aspenbio Pharma, Inc. Methods for inducing superovulation in ungulates
US8318457B2 (en) 2007-06-28 2012-11-27 Biogenerix Ag FSH producing cell clone
MY153976A (en) * 2007-11-01 2015-04-30 Merck Serono Sa Lh liquid formulations
DE202009009905U1 (de) * 2008-02-08 2009-10-29 Biogenerix Ag Flüssig-Formulierung von FSH
CN102309745B (zh) * 2008-09-17 2013-05-08 上海天伟生物制药有限公司 一种卵泡刺激素冻干针剂
DK2445552T3 (da) 2009-06-24 2016-01-25 Tecpharma Licensing Ag Indgivelsesapparat med klargøringsfunktion
EP2325194A1 (en) 2009-11-24 2011-05-25 Glycotope GmbH Process for the purification of glycoproteins
EP2515973B1 (de) 2009-12-23 2018-02-21 Tecpharma Licensing AG Injektionsvorrichtung mit einer nadelschutzhülse
WO2011076281A1 (de) 2009-12-23 2011-06-30 Tecpharma Licensing Ag Entfernen einer nadelschutzkappe von einer nadel
WO2011098129A1 (en) 2010-02-11 2011-08-18 Finox Ag Injection training dummy
CN102821782B (zh) * 2010-02-12 2015-07-15 印塔斯生物制药有限公司 促卵泡激素的液体配制品
EP2417982A1 (en) 2010-07-30 2012-02-15 Ferring B.V. Stabilization of gonadotropins
WO2012142961A1 (zh) * 2011-04-22 2012-10-26 上海天伟生物制药有限公司 一种低溶剂残留的糖蛋白组合物及其制备方法和用途
JP5750471B2 (ja) * 2013-05-22 2015-07-22 Ｊｃｒファーマ株式会社 組換え体ヒトｆｓｈの製造方法
CN103554269B (zh) * 2013-11-01 2015-02-11 广州联康生物科技有限公司 重组猪促卵泡激素融合蛋白
CN103539860B (zh) * 2013-11-01 2014-12-03 广州优联康医药科技有限公司 一种长效重组人促卵泡激素融合蛋白
CN103539861B (zh) * 2013-11-01 2015-02-18 广州联康生物科技有限公司 长效重组人促卵泡激素融合蛋白
SG11201603142YA (en) * 2013-11-12 2016-05-30 Cadila Healthcare Ltd Formulation for gonadotropins
BR112018003455A2 (pt) * 2015-09-17 2018-09-25 Glycotope Gmbh composição ou composição farmacêutica e uso da composição
GB201603280D0 (en) * 2016-02-24 2016-04-13 Ferring Bv Stable liquid gonadotropin formulation

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB839300A (en) * 1957-09-05 1960-06-29 Organon Labor Ltd Adrenocorticotropic hormone preparations and process for making same
US4659696A (en) † 1982-04-30 1987-04-21 Takeda Chemical Industries, Ltd. Pharmaceutical composition and its nasal or vaginal use
US5162306A (en) * 1987-01-23 1992-11-10 Donaldson Lloyd E Composition and method for producing superovulation in mammals
IT1206302B (it) * 1987-06-26 1989-04-14 Serono Cesare Ist Ricerca Ormone follicolo-stimolante urinario
FR2623715B1 (fr) * 1987-11-26 1990-12-21 Lafon Labor Structures peptidiques, immunogenes les contenant et leurs applications au controle de la fertilite
US5733572A (en) * 1989-12-22 1998-03-31 Imarx Pharmaceutical Corp. Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles
IE64738B1 (en) * 1990-03-20 1995-09-06 Akzo Nv Stabilized gonadotropin containing preparations
IT1250075B (it) * 1991-12-18 1995-03-30 Serono Cesare Ist Ricerca Composizioni farmaceutiche contenenti gonadotropine.
IL106524A (en) * 1992-07-31 2000-08-31 Genentech Inc Human growth hormone aqueous formulation
US5661125A (en) * 1992-08-06 1997-08-26 Amgen, Inc. Stable and preserved erythropoietin compositions
US5594091A (en) † 1994-02-21 1997-01-14 Takeda Chemical Industries, Ltd. Matrix for sustained-release preparation
TW426523B (en) † 1995-04-06 2001-03-21 Hoffmann La Roche Interferon solution
PT862452E (pt) * 1995-11-07 2004-04-30 Genentech Inc Formulacao de estabilizacao para o ngf
GB2317010A (en) * 1996-09-04 1998-03-11 Eev Ltd Gas sensor detecting only non-reflected light
TW518235B (en) * 1997-01-15 2003-01-21 Akzo Nobel Nv A gonadotropin-containing pharmaceutical composition with improved stability on prolong storage
US6287587B2 (en) † 1997-07-15 2001-09-11 Takeda Chemical Industries, Ltd. Process for producing sustained-release preparation by in-water drying
MY120063A (en) * 1997-12-09 2005-08-30 Lilly Co Eli Stabilized teriparatide solutions
JP2000151148A (ja) * 1998-11-13 2000-05-30 Mitsumi Electric Co Ltd 携帯用電子機器のコード接続構造

Also Published As

Publication number Publication date
EP0974359B2 (en) 2009-04-22
DK0974359T3 (da) 2003-03-03
KR20010083126A (ko) 2001-08-31
DE69904262D1 (de) 2003-01-16
PE20000939A1 (es) 2000-09-20
JP2002521342A (ja) 2002-07-16
DK0974359T4 (da) 2009-06-29
JP4719357B2 (ja) 2011-07-06
HK1026615A1 (en) 2000-12-22
PL346127A1 (en) 2002-01-28
DE69904262T2 (de) 2003-07-24
NO20010326L (no) 2001-03-20
ATE228850T1 (de) 2002-12-15
EP1188444B1 (en) 2005-11-09
DE69928296T2 (de) 2006-07-27
EP0974359A2 (en) 2000-01-26
NZ508874A (en) 2004-03-26
ATE308990T1 (de) 2005-11-15
EP1188444A1 (en) 2002-03-20
ES2183486T3 (es) 2003-03-16
AU4998099A (en) 2000-02-14
AU776823B2 (en) 2004-09-23
AR020618A1 (es) 2002-05-22
IL140984A0 (en) 2002-02-10
WO2000004913A1 (en) 2000-02-03
CA2335340A1 (en) 2000-02-03
BR9912243A (pt) 2001-10-16
PT974359E (pt) 2003-02-28
EP0974359B1 (en) 2002-12-04
EP0974359A3 (en) 2001-02-07
CN1309567A (zh) 2001-08-22
DE69928296D1 (de) 2005-12-15
NO20010326D0 (no) 2001-01-19
CA2335340C (en) 2013-03-05
SI0974359T1 (en) 2003-04-30
MY135913A (en) 2008-07-31
ES2250290T3 (es) 2006-04-16
ID28747A (id) 2001-06-28
DE69904262T3 (de) 2009-08-13

Similar Documents

Publication Publication Date Title
CO5090905A1 (es) Formulaciones de fsh o una variante de fsh procdutos y meto- dos
PT98710A (pt) Processo de preparacao de compostos de indolilo substituidos e de composicoes farmaceuticas que os contem
DK0563265T3 (da) Orale præparater
BR9406779A (pt) Complexos de inclusão de multicomponentes altamente solúveis contendo uma droga de tipo básico um ácido e uma ciclodextrina
AR042345A2 (es) Un procedimiento para la preparacion de una composicion farmaceutica para el tratamiento de aterosclerosis que contiene 8.9 - dehidroesterona o sus sales de la misma
IS4057A (is) Efni til að auka kyngetu
ES2074169T3 (es) Composicion desinfectante y procedimiento de desinfeccion.
NO954320D0 (no) Lyosfærer omfattende gonadotropin
ES2134187T3 (es) Preparaciones farmaceuticas.
ES2008865B3 (es) Procedimiento para preparar una composicion antiseptica.
BR9708553A (pt) Processo para limpeza de um substrato e uso de umsistema ativador de oxigenio molecular
CO5001019A1 (es) Composicion emulsionable para la represion de insectos, que se deriva del tipo de fenilpirazoles sustituidos en posi- cion 1, y no favorecen la formacion de cristales
ES2080256T3 (es) Mezcla esterilizante y metodo de esterilizacion.
MX191084B (es) Composiciones inhibidoras de trasnferencia de colorante que contienenagente tensioactivo.
SE9702680D0 (sv) New formulation
DK0633763T3 (da) Kosmetiske eller farmaceutiske sammensætninger indeholdende deacylerede glycerophospholipider til topisk brug
EP0404085A3 (de) Verwendung von Pankreatin enthaltendem Futter oder Prämix für Rennpferde und Rennkamele
DE3750493D1 (de) Flüssige sterilisierende Zusammensetzung.
AU8332791A (en) Oral pharmaceutical compositions containing melatonin
AR003418A1 (es) Composición farmacéutica con actividad antiepiléptica que contiene ácido r(-)-n- (4,4-di(3-metiltien-2-il) but-3-enil)-nipecótico o sus sales y el procedimiento para su preparación.
ES2053039T3 (es) Procedimiento para impedir el cambio de color de los alimentos.
ES2175135T3 (es) Uso de galactanasa en piensos animales.
FR2687933B1 (fr) Produits antimottants, compositions contenant ces produits et traitements mettant ces produits en óoeuvre.
AR248351A1 (es) Una composicion en barra cosmetica transparente.
DK0640098T3 (da) S-gen fra hundecoronavirus og anvendelser deraf